The company said it was not yet established that the vaccine had caused the safety event and it was working with the FDA to resolve the pause. "Our goal is to successfully resolve this matter and ...

Hympavzi is Pfizer's second hemophilia treatment to receive FDA approval this year after the agency greenlit its hemophilia B gene therapy Beqvez in April. Analysts expect sales of Hympavzi to ...